Figure 1.

Regression of cutaneous metastases after 2 doses of p53MVA vaccine and pembrolizumab. (A) The treatment schema: p53MVA vaccine and pembrolizumab were given concurrently every 3 weeks for 3 cycles. Pembolizumab alone was then administered every 3 weeks for an additional 4 doses. (B) Patient's skin pre- and 9 weeks post-treatment: before treatment (left) diffuse skin metastases covering 50% of the body area were visible. After 2 cycles of combined therapy (right) significant improvement was noted. (C) Pre- and post-treatment histopathology: pre-treatment skin punch biopsy (left) shows tumor nests composed of pleomorphic cells present predominantly within lymphovascular spaces. Post-treatment biopsy (right) demonstrates mild fibrosis and superficial perivascular lymphocytic infiltrate with no residual malignant cells present.